Investigational Drug Information for HGP0904
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug HGP0904?
HGP0904 is an investigational drug.
There have been 7 clinical trials for HGP0904.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 16th 2019.
The most common disease conditions in clinical trials are Hypertension, Dyslipidemias, and Hyperlipoproteinemias. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Seoul National University Bundang Hospital, and [disabled in preview].
There is one US patent protecting this investigational drug and twenty-five international patents.
Summary for HGP0904
| US Patents | 1,160 |
| International Patents | 25,319 |
| US Patent Applications | 7,110 |
| WIPO Patent Applications | 557 |
| Japanese Patent Applications | 56 |
| Clinical Trial Progress | Phase 3 (2019-07-16) |
| Vendors | 92 |
Recent Clinical Trials for HGP0904
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia | Hanmi Pharmaceutical Company Limited | Phase 3 |
| A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 |
| A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 |
Clinical Trial Summary for HGP0904
Top disease conditions for HGP0904
Top clinical trial sponsors for HGP0904
US Patents for HGP0904
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HGP0904 | See Plans and Pricing | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| HGP0904 | See Plans and Pricing | Combination therapy | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| HGP0904 | See Plans and Pricing | Compounds useful for the treatment of metabolic disorders and synthesis of the same | North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for HGP0904
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| HGP0904 | European Patent Office | EP3083573 | 2033-12-18 | See Plans and Pricing |
| HGP0904 | World Intellectual Property Organization (WIPO) | WO2015095097 | 2033-12-18 | See Plans and Pricing |
| HGP0904 | European Patent Office | EP2981556 | 2033-04-02 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
